Natural production and functional effects of alternatively spliced interleukin-4 protein in asthma

We have previously described an alternatively spliced isoform of IL-4 mRNA that omits exon 2 and is termed IL-4 delta 2. However, the natural production of IL-4 delta 2 protein and its association with disease have not been previously assessed due to unavailability of an antibody that interacts with IL-4 delta 2 without cross-reactivity with full length IL-4. We used a unique monoclonal antibody (mAb) that reacts with IL-4 delta 2, but not with IL-4, and observed that IL-4 delta 2 is naturally produced by T cells from patients with asthma, but not from healthy controls. The kinetics of IL-4 delta 2 and IL-4 production by phorbol myristate acetate (PMA)/ionomycin-activated cells differed, with IL-4 delta 2 increasing at 48-72 h and IL-4 peaking at 24 h. The steady-state levels of IL-4 delta 2 mRNA varied significantly among the donors and were discordant with the corresponding protein levels, suggesting post-transcriptional regulation of protein production. Polarized Th1 or Th2 lymphocytes were not a major source of IL-4 delta 2. Stimulation of cultured T lymphocytes with IL-4 delta 2 caused elevated production of IFN-gamma, IL-10, IL-6, MCP-1, and TNF-alpha, with notable differences between patients and controls in the production of IFN-gamma, IL-10, and IL-6. Thus, IL-4 delta 2 is natively produced not only as mRNA but also as a protein by cells other than Th1 or Th2. It is regulated post-transcriptionally, is associated with allergic asthma, and regulates production of other cytokines by primary T lymphocytes. Alternatively spliced interleukin-4 may be a new biomarker, a pathophysiological player, and possibly a molecular target for future therapies in asthma. Published by Elsevier Ltd.